+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Stomach Cancer Treatment Market by Treatment Type, Route of Administration, Distribution Channel, Stage, End User, Histologic Type - Global Forecast to 2030- Product Image
Stomach Cancer Treatment Market by Treatment Type, Route of Administration, Distribution Channel, Stage, End User, Histologic Type - Global Forecast to 2030- Product Image
Sale

Stomach Cancer Treatment Market by Treatment Type, Route of Administration, Distribution Channel, Stage, End User, Histologic Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012198
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Stomach Cancer Treatment Market grew from USD 5.55 billion in 2024 to USD 6.10 billion in 2025. It is expected to continue growing at a CAGR of 9.63%, reaching USD 9.64 billion by 2030.

Navigating the Evolving Terrain of Stomach Cancer Therapeutics

Stomach cancer remains one of the most formidable challenges in oncology, driving relentless research efforts across academia and industry. Its complex etiology and often late-stage presentation contribute to high mortality rates, demanding innovative therapeutic strategies. Recent breakthroughs in molecular profiling and immunotherapy have begun to reshape the clinical management paradigm, heralding a new era of personalized interventions. This executive summary distills critical developments, regulatory considerations, and market drivers that define the current treatment landscape.

Through rigorous analysis of treatment modalities, market segmentation, regional variations, and competitive dynamics, this summary equips decision-makers with a comprehensive view of opportunities and obstacles. It highlights how emerging technologies intersect with evolving healthcare policies to influence patient access and clinical outcomes. By synthesizing key insights from tariff changes to actionable recommendations, this overview prepares stakeholders to navigate uncertainties and capitalize on transformative trends shaping gastric oncology.

Revolutionizing Therapeutic Approaches in Gastric Oncology

Over the past five years, the gastric oncology landscape has experienced transformative shifts driven by scientific breakthroughs and regulatory support. Precision medicine initiatives have advanced molecular diagnostics, enabling clinicians to stratify patients based on genetic biomarkers and tailor therapies accordingly. Immuno-oncology agents targeting checkpoint pathways have moved from experimental stages to frontline settings, altering standard-of-care algorithms. Concurrently, advances in targeted therapies that inhibit EGFR, HER2, and VEGF pathways are expanding treatment options for subpopulations defined by specific tumor profiles.

As multidisciplinary care models evolve, integration of neoadjuvant and adjuvant regimens has demonstrated improved survival outcomes. Technological innovations in radiotherapy delivery enhance treatment precision and reduce collateral tissue damage, while surgical techniques such as minimally invasive total gastrectomy improve postoperative recovery. These collective advances underscore a shift from one-size-fits-all protocols to nuanced, combination-driven strategies that address tumor heterogeneity and resistance mechanisms.

Assessing the Ripple Effects of US Tariff Policies on Treatment Access

In 2025, the United States introduced a set of revised tariffs on imported active pharmaceutical ingredients and biologics pertinent to stomach cancer treatment. These measures have intensified scrutiny of global supply chains and prompted manufacturers to reassess sourcing strategies. Companies reliant on overseas suppliers for platinum-based chemotherapy agents and monoclonal antibodies have encountered elevated production costs, leading to strategic shifts toward domestic manufacturing and alternative supplier partnerships.

The cumulative impact of these tariff changes extends beyond cost structures, influencing pricing negotiations with payers and reimbursement frameworks. Stakeholders are responding by forging collaborative agreements that ensure streamlined logistics and mitigate potential drug shortages. Realigning procurement practices and investing in localized production facilities have emerged as core tactics to preserve market access and sustain treatment affordability in the face of evolving trade policies.

Unveiling Market Dynamics Through Multidimensional Segmentation

A comprehensive understanding of stomach cancer treatment requires examining the market through multiple segmentation lenses. When evaluating based on Treatment Type, chemotherapy continues to dominate with fluorouracil-based regimens complemented by platinum- and taxane-based combinations, while immunotherapy segments focusing on CTLA-4 and PD-1 inhibitors gain traction among biomarker-enriched cohorts. Radiotherapy strategies now encompass both brachytherapy and external beam techniques, and surgical interventions range from partial to total gastrectomy. Targeted therapies inhibiting EGFR, HER2, and VEGF pathways further diversify the therapeutic arsenal.

Considering Route of Administration, intravenous delivery retains widespread use for systemic agents even as oral formulations increase patient convenience and adherence. Distribution Channel dynamics highlight hospitals as primary dispensing hubs, with online and retail pharmacies bridging access for outpatient and homecare settings. Disease Stage analysis underscores distinct treatment algorithms for stages I through IV, guiding modality selection and intensity. The End User landscape spans homecare models, hospital environments, and specialized oncology clinics, each presenting unique logistical and reimbursement challenges. Histologic Type segmentation reveals that adenocarcinoma remains predominant, while carcinoid tumors, gastrointestinal stromal tumors, and lymphoma subtypes demand tailored approaches and research investment.

Regional Frontiers: Contrasting Gastric Cancer Treatment Trends Across Geographies

Regional insights illuminate how geography shapes access, adoption rates, and reimbursement policies across stomach cancer care. In the Americas, robust clinical trial activity and established biopharmaceutical infrastructure accelerate the uptake of novel immunotherapies and targeted agents. Payers in this region increasingly emphasize real-world evidence to inform coverage decisions, driving manufacturers to demonstrate tangible value through outcomes data.

Europe, the Middle East & Africa exhibit heterogeneous regulatory environments and economic capacities, resulting in varied rollout timelines for advanced therapies. Strategic partnerships with regional health authorities and patient advocacy groups are pivotal to overcoming market entry barriers. Meanwhile, Asia-Pacific markets showcase rapid growth fueled by expanding healthcare budgets and rising incidence rates. Localized production initiatives and government support for innovative medicines foster a competitive landscape where domestic and multinational companies compete to capture emerging demand.

Competitive Intelligence: Profiling Leading Innovators and Market Players

Leading pharmaceutical and biotechnology companies are at the forefront of driving innovation in stomach cancer care through diversified pipelines and strategic collaborations. Major organizations are investing heavily in next-generation immuno-oncology platforms, combining checkpoint inhibitors with novel adjuvants to achieve synergistic effects. Simultaneously, established firms leverage their global manufacturing networks to enhance supply chain resilience in response to tariff-induced uncertainties.

Smaller biotech innovators are carving niches by focusing on rare histologic subtypes and pioneering targeted therapies with first-in-class mechanisms. Collaborative research partnerships between academia and industry accelerate translational efforts, facilitating rapid movement from bench to bedside. In parallel, contract research organizations and specialty contract manufacturers play critical roles in optimizing trial design and scaling production, respectively, thereby shaping competitive dynamics and fostering an ecosystem of shared expertise and risk.

Strategic Imperatives for Stakeholders in Gastric Cancer Care

To capitalize on growth opportunities within the stomach cancer treatment landscape, industry leaders should prioritize strategic diversification of pipelines by integrating novel immunotherapy combinations with existing chemotherapy and targeted regimens. Strengthening supply chains through domestic manufacturing investments and alternative sourcing agreements will mitigate the impact of external tariff pressures. Collaborative ventures with contract research and manufacturing partners can expedite clinical development timelines and ensure scalability for commercial launch.

Engaging payers early in the development process to co-design evidence-generation studies will streamline reimbursement negotiations and foster value-based contracting. Organizations should also enhance patient engagement initiatives, leveraging digital health platforms to capture real-world outcomes and improve adherence in both intravenous and oral therapy settings. Finally, cultivating regional expertise through local partnerships and regulatory insight teams will facilitate more efficient market entry across diverse geographies.

Rigorous Analytical Framework Underpinning Our Insights

This report’s analysis rests on a rigorous methodology that synthesizes comprehensive secondary research with targeted primary interviews. Industry databases, peer-reviewed literature, regulatory filings, and company disclosures provided a robust foundation for trend identification and competitive mapping. Expert insights were gathered through structured interviews with oncologists, payers, supply chain specialists, and clinical researchers to validate assumptions and enrich contextual understanding.

Data triangulation methods ensured consistency across sources, while qualitative analysis techniques uncovered nuanced market drivers and barriers. A thematic approach to segmentation and regional assessment allowed for coherent integration of quantitative and qualitative findings. This multi-faceted framework guarantees that the insights presented herein reflect both empirical data and practitioner perspectives, offering stakeholders a reliable basis for strategic decision-making.

Integrating Insights: Charting the Future of Gastric Oncology

The evolving stomach cancer treatment landscape presents a confluence of scientific innovation, regulatory change, and market dynamics that collectively shape patient outcomes and commercial potential. From advancements in precision diagnostics and immune modulation to the strategic responses prompted by trade policy shifts, stakeholders must navigate a complex environment marked by both opportunities and challenges. Multidimensional segmentation and regional variation add further layers of complexity, underscoring the need for tailored strategies across product development, market access, and operational execution.

By synthesizing competitive intelligence, tariff impact analysis, and actionable recommendations, this executive summary offers a cohesive narrative to guide industry leaders. As the battlefield of gastric oncology expands, those organizations that integrate these insights into their strategic planning processes will be best positioned to deliver therapeutic breakthroughs, optimize stakeholder value, and ultimately improve patient care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
      • Fluorouracil-Based
      • Platinum-Based
      • Taxane-Based
    • Immunotherapy
      • Ctla-4 Inhibitors
      • Pd-1 Inhibitors
    • Radiotherapy
      • Brachytherapy
      • External Beam
    • Surgery
      • Partial Gastrectomy
      • Total Gastrectomy
    • Targeted Therapy
      • Egfr Inhibitors
      • Her2 Inhibitors
      • Vegf Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Stage
    • Stage I
    • Stage Ii
    • Stage Iii
    • Stage Iv
  • End User
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Histologic Type
    • Adenocarcinoma
    • Carcinoid Tumors
    • Gist
    • Lymphoma
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Merck Sharp & Dohme Corp.
  • AstraZeneca PLC
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Stomach Cancer Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Fluorouracil-Based
8.2.2. Platinum-Based
8.2.3. Taxane-Based
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.4. Radiotherapy
8.4.1. Brachytherapy
8.4.2. External Beam
8.5. Surgery
8.5.1. Partial Gastrectomy
8.5.2. Total Gastrectomy
8.6. Targeted Therapy
8.6.1. Egfr Inhibitors
8.6.2. Her2 Inhibitors
8.6.3. Vegf Inhibitors
9. Stomach Cancer Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Stomach Cancer Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Stomach Cancer Treatment Market, by Stage
11.1. Introduction
11.2. Stage I
11.3. Stage Ii
11.4. Stage Iii
11.5. Stage Iv
12. Stomach Cancer Treatment Market, by End User
12.1. Introduction
12.2. Homecare
12.3. Hospitals
12.4. Specialty Clinics
13. Stomach Cancer Treatment Market, by Histologic Type
13.1. Introduction
13.2. Adenocarcinoma
13.3. Carcinoid Tumors
13.4. Gist
13.5. Lymphoma
14. Americas Stomach Cancer Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Stomach Cancer Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Stomach Cancer Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche AG
17.3.2. Bristol-Myers Squibb Company
17.3.3. Merck Sharp & Dohme Corp.
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Takeda Pharmaceutical Company Limited
17.3.7. Daiichi Sankyo Company, Limited
17.3.8. Sanofi S.A.
17.3.9. Pfizer Inc.
17.3.10. Amgen Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. STOMACH CANCER TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. STOMACH CANCER TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. STOMACH CANCER TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CARCINOID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 77. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 79. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 83. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 88. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 90. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 91. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 141. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 146. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 147. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 154. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 155. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 157. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 158. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 174. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 177. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 179. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 183. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 185. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 189. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 190. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 191. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 194. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 229. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 234. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 235. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 238. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 251. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 253. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 254. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 255. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 256. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 257. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 260. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 262. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 267. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 268. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 295. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 297. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 299. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 300. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 301. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 304. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 306. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 308. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 309. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 311. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 312. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 315. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY HISTOLOGIC TYPE, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)

Companies Mentioned

The companies profiled in this Stomach Cancer Treatment market report include:
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Merck Sharp & Dohme Corp.
  • AstraZeneca PLC
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Amgen Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.64 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Disease Indication, By Route Of Administration, By Drug Class, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Stomach Cancer Treatment - Global Strategic Business Report - Product Image

Stomach Cancer Treatment - Global Strategic Business Report

  • Report
  • 74 Pages
  • Global
From
Gastric Cancer Drugs Market by Therapeutic Class, Treatment Line, Distribution Channel, Route of Administration, Dosage Form, Therapy Type - Global Forecast to 2030 - Product Image

Gastric Cancer Drugs Market by Therapeutic Class, Treatment Line, Distribution Channel, Route of Administration, Dosage Form, Therapy Type - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
HER2-positive Gastric Cancer- Pipeline Insight, 2025 - Product Image

HER2-positive Gastric Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From
Gastric Cancer- Pipeline Insight, 2025 - Product Image

Gastric Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • 550 Pages
  • Global
From

About the Stomach Cancer Drug Market

Stomach cancer, also known as gastric cancer, is a type of cancer that affects the lining of the stomach. Oncology drugs are used to treat this type of cancer, and the stomach cancer drug market is a subset of the larger oncology drug market. These drugs are used to treat both early and advanced stages of stomach cancer, and can be administered orally, intravenously, or through injections. They can also be used in combination with other treatments such as chemotherapy and radiation therapy. The stomach cancer drug market is highly competitive, with many companies developing and marketing drugs for the treatment of this type of cancer. Some of the major players in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to improve the treatment of stomach cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.